Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway

Wu,Jian; Zhang,Xingxing; Wang,Yaohui; Sun,Qingmin; Chen,Min; Liu,Shenlin; Zou,Xi

doi:10.3892/or.2017.6155

Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway

Authors:
- Jian Wu
- Xingxing Zhang
- Yaohui Wang
- Qingmin Sun
- Min Chen
- Shenlin Liu
- Xi Zou
View Affiliations

Affiliations: Central Laboratory, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Digestive Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Pathology Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Clinical Pharmacy Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, General Internal Medicine Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Oncology Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China
Published online on: December 14, 2017 https://doi.org/10.3892/or.2017.6155
Pages: 1181-1190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Licochalcone A (LicA) is a chalcone extracted from liquorice which has been used as a traditional Chinese medicine for many generations. Increased glucose consumption and glycolytic activity are important hallmarks of cancer cells, and hexokinase 2 (HK2) upregulation is a major contributor to the elevation of glycolysis. Recently, the antitumor activities of LicA have been reported in various cancers; however, its effect on tumor glycolysis in gastric cancer and the underlying mechanisms are completely unknown. In vitro, cell proliferation and clonogenic survival were substantially inhibited after LicA treatment. LicA reduced HK2 expression, and both glucose consumption and lactate production in gastric cancer cells were significantly suppressed. Mechanistic investigations revealed that multiple signaling pathways including Akt, ERK and NF‑κB were suppressed by LicA. Further studies demonstrated that the inhibition of glycolysis by LicA was mainly attributed to the blockade of the Akt signaling pathway, and the suppression of glycolysis was substantially attenuated when Akt was exogenously overexpressed. In addition to the role in the inhibition of glycolysis, reduction in HK2 was confirmed to be involved in the induction of cell apoptosis. The apoptosis induced by LicA was substantially impaired after HK2 overexpression in gastric cancer cells. The in vivo experiment showed that MKN45 xenograft growth was markedly delayed after LicA treatment and HK2 expression in LicA‑treated tissues was markedly decreased. All of these data demonstrated that blockade of the Akt/HK2 pathway was the underlying mechanism required for LicA to exert its biological activities in glycolysis inhibition and apoptosis induction.

View Figures

View References

1	Lee N and Kim D: Cancer Metabolism: Fueling more than just growth. Mol Cells. 39:847–854. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
3	Doherty JR and Cleveland JL: Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 123:3685–3692. 2013. View Article : Google Scholar : PubMed/NCBI
4	Rho M, Kim J, Jee CD, Lee YM, Lee HE, Kim MA, Lee HS and Kim WH: Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res. 27A:1–258. 2007.
5	Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al: Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res. 7:1438–1445. 2009. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Wu K, Shi L, Xiang F, Tao K and Wang G: Prognostic significance of the metabolic marker hexokinase-2 in various solid tumors: A meta-analysis. PLoS One. 11:e01662302016. View Article : Google Scholar : PubMed/NCBI
7	Zhang ZF, Feng XS, Chen H, Duan ZJ, Wang LX, Yang D, Liu PX, Zhang QP, Jin YL, Sun ZG, et al: Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol. 16:572016. View Article : Google Scholar : PubMed/NCBI
8	Kwee SA, Hernandez B, Chan O and Wong L: Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: Association with survival. PLoS One. 7:e465912012. View Article : Google Scholar : PubMed/NCBI
9	Hamabe A, Yamamoto H, Konno M, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto K, et al: Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci. 105:1100–1108. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yu X, Deng Q, Li W, Xiao L, Luo X, Liu X, Yang L, Peng S, Ding Z, Feng T, et al: Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFα and ROS production. Oncotarget. 6:1995–2008. 2015. View Article : Google Scholar : PubMed/NCBI
11	Yu X, Li W, Deng Q, You S, Liu H, Peng S, Liu X, Lu J, Luo X, Yang L, et al: Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Mol Carcinog. 56:1414–1426. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lee KW, Bode AM and Dong Z: Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer. 11:211–218. 2011. View Article : Google Scholar : PubMed/NCBI
13	Chen X, Liu Z, Meng R, Shi C and Guo N: Antioxidative and anticancer properties of Licochalcone A from licorice. J Ethnopharmacol. 198:331–337. 2017. View Article : Google Scholar : PubMed/NCBI
14	Hu J and Liu J: Licochalcone A attenuates kipopolysaccharide-induced acute kidney injury by inhibiting NF-κB activation. Inflammation. 39:569–574. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wang L, Yang R, Yuan B, Liu Y and Liu C: The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 5:310–315. 2015. View Article : Google Scholar : PubMed/NCBI
16	Bortolotto LF, Barbosa FR, Silva G, Bitencourt TA, Beleboni RO, Baek SJ, Marins M and Fachin AL: Cytotoxicity of trans-chalcone and licochalcone A against breast cancer cells is due to apoptosis induction and cell cycle arrest. Biomed Pharmacother. 85:425–433. 2017. View Article : Google Scholar : PubMed/NCBI
17	Tang ZH, Chen X, Wang ZY, Chai K, Wang YF, Xu XH, Wang XW, Lu JH, Wang YT, Chen XP, et al: Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. Sci Rep. 6:262412016. View Article : Google Scholar : PubMed/NCBI
18	Park MR, Kim SG, Cho IA, Oh D, Kang KR, Lee SY, Moon SM, Cho SS, Yoon G, Kim CS, et al: Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phosphorylation-mediated TRAIL expression in head and neck squamous carcinoma FaDu cells. Food Chem Toxicol. 77:34–43. 2015. View Article : Google Scholar : PubMed/NCBI
19	Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL, Hsueh JT and Hsieh YH: Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. Oncotarget. 6:28851–28866. 2015. View Article : Google Scholar : PubMed/NCBI
20	Huang HC, Tsai LL, Tsai JP, Hsieh SC, Yang SF, Hsueh JT and Hsieh YH: Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression. Tumour Biol. 35:12139–12149. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kim YH, Shin EK, Kim DH, Lee HH, Park JH and Kim JK: Antiangiogenic effect of licochalcone A. Biochem Pharmacol. 80:1152–1159. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
23	Kinghorn AD, DE Blanco EJ, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, et al: Discovery of anticancer agents of diverse natural origin. Anticancer Res. 36:5623–5637. 2016. View Article : Google Scholar : PubMed/NCBI
24	Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D and Zheng Q: Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways. Sci Rep. 5:103362015. View Article : Google Scholar : PubMed/NCBI
25	Lee JW, Lee SM, Lee MS and Shin HC: Role of ^¹8F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. Eur J Nucl Med Mol Imaging. 39:1425–1434. 2012. View Article : Google Scholar : PubMed/NCBI
26	Coupe NA, Karikios D, Chong S, Yap J, Ng W, Merrett N and Lin M: Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Ann Nucl Med. 28:128–135. 2014. View Article : Google Scholar : PubMed/NCBI
27	Watanabe Y, Suefuji H, Hirose Y, Kaida H, Suzuki G, Uozumi J, Ogo E, Miura M, Takasu K, Miyazaki K, et al: ¹⁸F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 97:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
28	Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, Li YH and Xu RH: Expressions of hypoxia-inducible factor-1α and hexokinase-II in gastric adenocarcinoma: The impact on prognosis and correlation to clinicopathologic features. Tumour Biol. 32:159–166. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yin L, Wang X, Luo C, Liu H, Zhang L, Zhang H and Zhang Y: The value of expression of M2-PK and VEGF in patients with advanced gastric cancer. Cell Biochem Biophys. 67:1033–1039. 2013. View Article : Google Scholar : PubMed/NCBI
30	Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH and Cho JY: Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol. 18:4037–4043. 2012. View Article : Google Scholar : PubMed/NCBI
31	Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 25:4777–4786. 2006. View Article : Google Scholar : PubMed/NCBI
32	Chen GQ, Tang CF, Shi XK, Lin CY, Fatima S, Pan XH, Yang DJ, Zhang G, Lu AP, Lin SH, et al: Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism. Oncotarget. 6:24148–24162. 2015.PubMed/NCBI
33	Li W, Ma X, Li N, Liu H, Dong Q, Zhang J, Yang C, Liu Y, Liang Q, Zhang S, et al: Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway. Exp Cell Res. 349:320–327. 2016. View Article : Google Scholar : PubMed/NCBI
34	Li W, Gao F, Ma X, Wang R, Dong X and Wang W: Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis. Oncotarget. 8:32586–32599. 2017.PubMed/NCBI
35	Zhuo B, Li Y, Li Z, Qin H, Sun Q, Zhang F, Shen Y, Shi Y and Wang R: PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. Biochem Biophys Res Commun. 464:401–406. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zhou Y, Lu N, Qiao C, Ni T, Li Z, Yu B, Guo Q and Wei L: FV-429 induces apoptosis and inhibits glycolysis by inhibiting Akt-mediated phosphorylation of hexokinase II in MDA-MB-231 cells. Mol Carcinog. 55:1317–1328. 2016. View Article : Google Scholar : PubMed/NCBI
37	Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB and Song YS: Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 14:345–353. 2014. View Article : Google Scholar : PubMed/NCBI
38	Wang L, Wang J, Xiong H, Wu F, Lan T, Zhang Y, Guo X, Wang H, Saleem M, Jiang C, et al: Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine. 7:50–61. 2016. View Article : Google Scholar : PubMed/NCBI
39	Wang J, Duan Z, Nugent Z, Zou JX, Borowsky AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, et al: Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 378:69–79. 2016. View Article : Google Scholar : PubMed/NCBI